Cimzia (certolizumab pegol) - Astellas, UCB
Humira (adalimumab) - AbbVie
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Renal Involvement in Crohnâs Disease: An Uncommon Extraintestinal Manifestation (ACG 2026) - Aug 29, 2026 - Abstract #P1269; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "Psoriatic arthritis was initially managed with adalimumab which likely masked his underlying CD until formal diagnosis in 2018 after which he was transitioned to certolizumab...He was treated with pulse-dose and taper of corticosteroids with continuation of risankizumab...Figure: Interstitial inflammation, tubulitis, and an epithelioid granuloma. (Masson trichrome stain, 20x objective)" 
Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Nephrology • Psoriasis • Psoriatic Arthritis • Renal Calculi • Renal Disease • Sarcoidosis • Seronegative Spondyloarthropathies • TNFA
https://acg2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=R01PT1FGR0UyNjkyNQ&PosterID=829792&rnd=0.9760137
 
Brandon Izatt; MD; Siri Urquhart; MD
 
Aug 29, 2026
 
Prev Next